Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.670
-0.030 (-1.76%)
Jun 3, 2026, 10:41 AM EDT - Market open
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
284.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 260.50K | 137.06K | 111.03% |
| Dec 31, 2022 | 123.44K | -2.98M | -96.02% |
| Dec 31, 2021 | 3.10M | 2.40M | 343.92% |
| Dec 31, 2020 | 698.47K | -424.27K | -37.79% |
| Dec 31, 2019 | 1.12M | -2.92M | -72.22% |
| Dec 31, 2018 | 4.04M | 1.98M | 96.07% |
| Dec 31, 2017 | 2.06M | 1.09M | 113.04% |
| Dec 31, 2016 | 967.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Zentalis Pharmaceuticals | 26.87M |
| Lineage Cell Therapeutics | 14.78M |
| Opus Genetics | 11.98M |
| Fate Therapeutics | 6.32M |
| Armata Pharmaceuticals | 5.20M |
| Humacyte | 2.02M |
IKT News
- 21 days ago - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 21 days ago - Inhibikase Therapeutics Earnings release: Q1 2026 - Filings
- 21 days ago - Inhibikase Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Inhibikase Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Inhibikase Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Inhibikase Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study - TheFly
- 2 months ago - Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire